Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hammermann, Jutta
cASPerCF, NCT04966234 / 2019-004511-31: A New Posaconazole Dosing Regimen for Paediatric Patients With Cystic Fibrosis and Aspergillus Infection	Recruiting	2/3	135	Europe, RoW	Posaconazole 100 MG [Noxafil], gastro-resistant tablets Noxafil® 100 mg, Posaconazole 40 MG/ML, 105 ml Noxafil® 40 mg/ml oral suspension	Bambino Gesù Hospital and Research Institute, University of Exeter, Radboud University, Consorzio per Valutazioni Biologiche e Farmacologiche	Cystic Fibrosis, Aspergillosis	04/23	11/23